Oncology Revenue Cycle in 2026: How Drug Cost Inflation Is Reshaping Reimbursement Strategies

The oncology revenue cycle in 2026 looks very different than it did just a few years ago.

Rising drug acquisition costs, tighter payer scrutiny, evolving Medicare reimbursement rules, and growing prior authorization requirements have created a high-risk financial environment for oncology practices. With specialty drugs accounting for the majority of oncology revenue, even small reimbursement gaps can translate into significant losses.